Targeting ubiquitination for cancer therapies

被引:87
|
作者
Morrow, John Kenneth [1 ,2 ]
Lin, Hui-Kuan [3 ]
Sun, Shao-Cong [4 ]
Zhang, Shuxing [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Integrated Mol Discovery Lab, Houston, TX 77030 USA
[2] Univ Texas Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[4] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
关键词
cancer therapeutics; deubiquitinase; E3 ligase inhibition; high-throughput virtual screening; hot spots; in silico modeling; SCF complex; Skp2; inhibitors; small molecule inhibitors; ubiquitination; SMALL-MOLECULE INHIBITOR; ACTIVE PROTEASOME INHIBITOR; SINGLE-AGENT CARFILZOMIB; CELL-CYCLE ARREST; LIGASE CBL-B; MULTIPLE-MYELOMA; OPEN-LABEL; DEUBIQUITINASE INHIBITION; NEDD8-ACTIVATING ENZYME; UBC13-UEV1A INTERACTION;
D O I
10.4155/fmc.15.148
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.
引用
收藏
页码:2333 / 2350
页数:18
相关论文
共 50 条
  • [31] CURRENT APPROACHES TO TARGETING CANCER USING ANTIANGIOGENESIS THERAPIES
    SCOTT, PAE
    HARRIS, AL
    CANCER TREATMENT REVIEWS, 1994, 20 (04) : 393 - 412
  • [32] Targeting-PP2A-in-cancer: Combination therapies
    Mazhar, Sahar
    Taylor, Sarah E.
    Sangodkar, Jaya
    Narla, Goutham
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2019, 1866 (01): : 51 - 63
  • [33] Anti-cancer therapies targeting the tumor stroma
    Valeska Hofmeister
    David Schrama
    Jürgen C. Becker
    Cancer Immunology, Immunotherapy, 2008, 57 : 1 - 17
  • [34] Targeting the Hippo Pathway for Anti-cancer Therapies
    Gong, Rui
    Yu, Fa-Xing
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (35) : 4104 - 4117
  • [35] Anti-cancer therapies targeting the tumor stroma
    Hofmeister, Valeska
    Schrama, David
    Becker, Juergen C.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (01) : 1 - 17
  • [36] Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
    Dowsett, M
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S13 - S13
  • [37] Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
    M Dowsett
    Breast Cancer Research, 7
  • [38] An Update on the Role of Ubiquitination in Melanoma Development and Therapies
    Soysouvanh, Frederic
    Giuliano, Serena
    Habel, Nadia
    El-Hachem, Najla
    Pisibon, Celine
    Bertolotto, Corine
    Ballotti, Robert
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 20
  • [39] Targeting the regulatory enzymes in protein ubiquitination
    Zheng, Ning
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [40] Targeting metastatic prostate cancer: The search for innovative systemic therapies
    Berthold, Dominik R.
    Moore, Malcolm J.
    ONCOLOGY-NEW YORK, 2006, 20 (14): : 1787 - 1792